Interplay of nuclear receptors (ER, PR, and GR) and their steroid hormones in MCF-7 cells by Hegde, S.M. et al.
Interplay of nuclear receptors (ER, PR, and GR) and their steroid
hormones in MCF-7 cells
Shubha M. Hegde1 • M. Naveen Kumar1 • K. Kavya1 •
K. M. Kiran Kumar1 • Rashmi Nagesh1 • Rajeshwari H. Patil1 •
R. L. Babu2 • Govindarajan T. Ramesh3 • S. Chidananda Sharma1
Received: 11 April 2016 / Accepted: 29 August 2016
 Springer Science+Business Media New York 2016
Abstract Steroid hormones and their nuclear receptors
play a major role in the development and progression of
breast cancer. MCF-7 cells are triple-positive breast cancer
cells expressing estrogen receptor (ER), progesterone
receptor (PR), and glucocorticoid receptor (GR). However,
interaction and their role in expression pattern of activator
protein (AP-1) transcription factors (TFs) are not com-
pletely understood. Hence, in our study, MCF-7 cells were
used as an in vitro model system to study the interplay
between the receptors and hormones. MCF-7 cells were
treated with estradiol-17b (E2), progesterone (P4), and
dexamethasone (Dex), alone or in combination, to study
the proliferation of cells and expression of AP-1 genes.
MTT assay results show that E2 or P4 induced the cell
proliferation by more than 35 %, and Dex decreased the
proliferation by 26 %. E2 and P4 are found to increase ERa
by more than twofold and c-Jun, c-Fos, and Fra-1 AP-1 TFs
by more than 1.7-fold, while Dex shows opposite effect of
E2- or P4-induced effect as well as effect on the expression
of nuclear receptors and AP-1 factors. E2 antagonist Ful-
vestrant (ICI 182,780) found to reduce proliferation and
E2-induced expression of AP1-TFs, while P4 or Dex
antagonist Mifepristone (RU486) is found to block GR-
mediated expression of NRs and AP-1 mRNAs. Results
suggest that E2 and P4 act synergistically, and Dex acts as
an antagonist of E2 and P4.
Keywords Nuclear receptors  Steroid hormones  MCF-
7  AP-1  RT-PCR
Introduction
Mammary glands are the modified sweat glands developed
in females during and after puberty. Development of
mammary gland takes place under the influence of steroid
hormones, the estrogen and progesterone produced by the
ovary. The luminal epithelium of the gland contains
receptors for steroid hormones, and sequential activation of
hormonal signaling in the mammary epithelium is required
for the progression of morphogenesis [1]. The steroid
hormones in cooperation with pituitary hormones play a
major role in the induction of proliferation and differenti-
ation of epithelial and stromal cells leading ultimately to
the formation of ductal and alveolar structures during the
development of mammary gland [2]. Over-expression of
these reproductive hormones and their receptors leads to an
uncontrolled division of breast epithelial cells and metas-
tasis, causing breast cancer. Most of the breast cancer cases
are triple positive (ER, PR, and GR positive), and hence it
is important to know the role of each of these steroid
hormones, mechanism of their action, and expression of
these receptors in breast cancer.
Steroid hormone receptors belong to a nuclear receptor
super-family of proteins. They are sequestered in cytosol as
an inactive complex by binding to heat-shock proteins
(Hsps); upon binding to ligand or hormone, the steroid
receptor separates from Hsps, hormone-receptor complex
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dimerizes and translocates into the nucleus, binds to
specific regions of DNA, and transactivates the target genes
[3]. The receptors that lack AF-2 domain fail to recognize
HREs and hence do not mediate genomic pathways
involved in the expression of ligand-mediated responses.
However, steroid hormones also show nongenomic actions
that involve the membrane-associated receptor binding,
and activate second messengers, which in turn transactivate
the cascade pathway involving protein kinases (PKA or
PKC or PKB, MAPK, PI3K, Src kinases, EGF, etc.) [4].
ER, the classical steroid receptor, mainly exists as ERa or
ERb, and ERa-containing AF-2 element recruits p-160 co-
regulatory protein involved in recognizing estrogen
response elements (EREs) in the promoter region of the
target DNA. GR exists as GRa and GRb. GRa, like the
classical steroid receptor, lies in the cytoplasm as a com-
plex, binding to Hsps; upon binding of ligand glucocorti-
coid (GC), GRa is separated from Hsps and forms complex
with GC, which is then translocated and binds to GRE in
the nucleus and brings about activation of genes. Whereas,
GRb lacks LBD and hence cannot bind to hormone GC. PR
exists as PRa and PRb isoforms. Unlike ER and GR, both
the isoforms of PR are involved in tumorigenesis of breast
epithelial cells as they are transcribed from the same gene
via alternative promoter usage. Like ER and GR, PR iso-
forms also function as ligand-dependent transcription fac-
tors [5].
In HRE-independent genomic pathway, hormone-re-
ceptor dimer will not bind to hormone response element
(HRE), instead it will bind to HRE-like sites which serve as
orphan hormone binding sites, and the mechanism of action
involves the tethering of hormonal receptors to other DNA-
binding transcription factors (TFs), such as AP-1 or NF-
jB, and transcription of gene occurs. Activator protein-1
(AP-1) plays a critical role in the regulation of breast cells
proliferation as well as in the development of cancer. AP-1
TFs contain basic leucine zipper (bZIP) domain required
for DNA-ligand dimer formation and regulate various
cellular processes. They represent sequence-specific DNA-
binding transcription factors and consist of homo- or het-
erodimers, which are formed by either homodimer of Jun–
Jun (c-Jun, Jun-B, Jun-D), or Jun–Fos heterodimer (Jun–c-
Fos/Fra-1/Fra-2), or activating transcription factor (ATF)
proteins, in mammalian cells [6]. Various combinations of
Jun/Jun or Jun/Fos proteins regulate different cellular
processes such as proliferation, differentiation, and
angiogenesis.
Studies show that in the case of ERE-independent
genomic pathway, Estradiol-17b–AP1 complex found to
induce the expression of c-Jun and Cyclin D1 through ER–
Sp1 complex which in turn depends on the type of ligand,
the cell type, and also the receptor sub-types. It is also
proved that the specific residues in the second zinc finger
motif of ERb–DBD discriminate between classical mech-
anism of ER action and modulation of AP-1 and signal
transducer and activator of transcription (STAT-5) activi-
ties through tethering. These specific residues in the second
structure of zinc finger DBD region of ER were found to be
involved in the GR-mediated repression of AP-1 activity
[7].
Like estrogen, the progesterone and glucocorticoids also
act as the key regulators of proliferation, differentiation,
and development of breast cancer. However, the effect of
GC depends on the E2 concentration and the expression of
ERa in breast tumor cells. Studies using in vitro model
system show that GC inhibits the growth of ERa-positive
cells [8]. Estrogens and glucocorticoids have opposing
effects on the expression of respective nuclear receptor
mRNAs and specific AP-1 factors. AP-1 was found to be
upregulated by E2, while GC down-regulates the same
when acting simultaneously with E2 [9]. Similarly, GC and
mineralocorticoid (MC) cross-talk with PR to produce
progesterone—like effects in breast cancer cells. Although
GR and PR share some overlapping activity in mediating
local adhesion, their cross-talk effects in regulating cell
proliferation were found to be varied [10].
Fulvestrant (ICI 182,780) is a pure potent antagonist of
E2 that binds to ER in a competitive inhibitory manner.
When ICI 182,780 binds to ER, the receptor dimerization is
impaired with the energy-dependent nucleocytoplasmic
shuttling, which occurs and blocks the nuclear localization
of the receptor [11]. Thus, ICI exerts selective estrogen
receptor down-regulation (SERD) with anti-proliferative
activity and induction of apoptosis. The ICI-ER complex
makes ER unavailable and unresponsive towards E2, and
thereby ER proteins are degraded, and hence the tran-
scription of ER-targeted genes are down-regulated [12].
The binding of ICI 182,780 is different from that of ER-
Tamoxifen as it may act as E2 agonist or antagonist [13].
The degradation of ER protein by ICI leads to the complete
inhibition of E2-mediated signaling through ER [12].
Mifepristone (RU486) is a synthetic 19-norsteroid and is a
potent antagonist of progesterone and also glucocorticoids.
In our studies, we used ICI 182,780 and RU486 to inhibit
the specific action of E2, GC, and P4 on the expression of
genes in MCF-7 cells.
Different types of adenocarcinoma cells show variable
pattern of mRNA expression of hormone receptors and AP-
1 TFs. Earlier studies carried out in our laboratory show the
differential expression pattern of ERa and AP-1 TFs, in
both ERa-responsive positive breast cancer cells (MCF-7)
and ERa-nonresponsive lung epithelial cells (A549). In
MCF-7 cells, E2 induced cell proliferation and proliferative
genes such as ERa, c-Jun, Fra-1 and Fra-2 AP-1 TFs.
Whereas, Tamoxifen, used as antagonist of E2, found to
down-regulate the expression of ERa as well as Jun and
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Fos AP-1 TFs, showing that ERa-positive cells in a breast
tumor respond to tamoxifen treatment. Since, ER-nonre-
sponsive lung adenocarcinoma cells do not express ER, the
ER-mediated proliferation of cells was not observed.
However, AP-1 TFs were expressed independent of ER in
A549 cells [14, 15]. In spite of such several studies, the
mechanism and cross-talk between ER, PR, and GR, and
their role in the regulation of expression of AP-1 factors in
breast cancer etiology remain unclear. Hence, the present
study was undertaken to use the analogues of steroid hor-
mones (Estradiol-17b, Progesterone, and Dexamethasone)
and specific antagonists to modulate specific receptors
expression and the cross-talk between different steroid
hormone receptors. Further, the role of steroid receptors
and their hormones and the expression pattern of AP-1
factors were studied using triple-positive MCF-7 cells as a
model system under in vitro conditions.
Materials and methods
Materials
Human breast cancer cells (MCF-7) were purchased from
NCCS (Pune, India); Estradiol-17b, Progesterone, Dex-
amethasone, Fulvestrant (ICI 182, 780), Mifepristone
(RU486), forward and reverse primers for ERa, ERb [14],
different AP-1 factors [15], and PR and GR were purchased
from Sigma-Aldrich (St Louis, USA). Superscript reverse
transcriptase for RT-PCR was purchased from Invitrogen
(CA, USA). RPMI 1640 media, fetal bovine serum (FBS),
penicillin, streptomycin, glutamine, 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), dime-
thyl sulfoxide (DMSO), Sodium Pyruvate, and Trypan blue
dye were purchased from Himedia (Mumbai, India).
Antibody to GAPDH was purchased from NeoBiolab (MA,
USA), and anti-rabbit antibody-HRP conjugate was pur-
chased from Imgenex India Pvt. Ltd. (Bhubaneswar, India).
Antibody to ERa was a generous gift from Prof. A. J. Rao,
PR and anti-mouse antibody-HRP conjugate were gifts
from Prof. Anjali Karande, Indian Institute of Science,
Bengaluru, India. Taq DNA polymerase (1 U/ll) and
Luminata Forte Western HRP substrate were procured
from Merck-Millipore (Mumbai, India).
Culturing of MCF-7 cells and treatment
MCF-7 cells were grown in 75 cm2 culture flask in RPMI
1640 media with 10 % FBS, 100 U/ml penicillin, 100 lg/
ml streptomycin, 2 mM L-glutamine, and 1 mM sodium
pyruvate. Cells were cultured in a humidified atmosphere at
37 C by passing 5 % CO2 in an incubator. Flask
containing 90–100 % confluent cells were sub-cultured in
96-well plate (3 9 103 cells/well) or in 6-well plate
(5 9 105 cells/well) for the treatment with different
modulators.
MTT assay
MTT assay for cell viability was carried out as per the
protocol described earlier [16]. In brief, MCF-7 cells
(3 9 103 cells/well) in 200 ll of RPMI 1640 media were
seeded into 96-well culture plate and incubated overnight
at 37 C with the supply of 5 % CO2. Cells were treated
with or without different concentrations of E2
(10–1000 nM), or P4 (10–1000 nM), or Dex (10–500 lM),
or ICI 182,780 (10–100 nM), or RU486 (10–1000 nM),
incubated for 48 h, washed with PBS, treated with 20 ll of
MTT (5 mg/ml), and incubated further for 4 h at 37 C
with the supply of 5 % CO2 in an incubator. Live cells take
up the yellow compound MTT, and mitochondrial enzymes
reduce it to insoluble blue formazan products which were
dissolved in DMSO (100 ll), and absorbance was mea-
sured at 540 nm using spectrophotometer. The effect of E2
or Dex or P4 or ICI 182,780 and RU486 on cell viability
was calculated and represented graphically as % of viable
cells compared to control.
RNA isolation and semi-quantitative PCR
Overnight cultured MCF-7 cells (5 9 105 cells/well) in a
6-well plate were treated with or without E2 (100 nM), or
Dex (100 nM), or P4 (150 nM) or E2 (100 nM) and Dex
(100 nM) or P4 (150 nM) and Dex (100 nM) or E2
(100 nM) and P4 (150 nM) or E2 (100 nM) and Dex
(100 nM) and P4 (150 nM) or E2 (100 nM) and ICI
182,780 (10 nM) or Dex (100 nM) and RU486 (10 nM),
or P4 (150 nM) and RU486 (10 nM) for 48 h. Total RNA
was isolated from each of the samples using ‘‘Trizol
reagent’’ and as per the instructions provided by the
manufacturer. Reverse transcription of RNA and PCR
analysis was carried out as per the protocol described
earlier [17]. In brief, total RNA (2 lg) was reverse tran-
scribed using Oligo (dT) primers and superscript reverse
transcriptase. The cDNA was subjected to 30 cycles of
PCR using different forward and reverse primers of
nuclear receptors (NRs) or AP-1 factors using appropriate
annealing temperatures as indicated earlier [14] and in
Table 1 in a gradient Eppendorf thermocycler. Amplified
PCR products were analyzed on 1 % agarose gel using
19 TAE buffer. Relative mRNA levels were quantified
using image analysis software (ImageJ). The expression
of b-actin mRNA was used as a positive control and for
normalization.
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Immunoblotting of ERa and PR
Total protein of MCF-7 cell extracts was prepared and
analyzed by western blotting as per the protocol descri-
bed earlier [17]. Control and treated cells seeded in a
6-well plate were washed thrice with PBS followed by
the addition of 0.2 ml of cold lysis buffer [Tris–HCl
(50 mM) pH 8.0, NaCl (150 mM), NP-40 (1.0 %), and
PMSF (100 lM)]. Cells were scraped, and suspensions
were gently transferred to the pre-cooled Eppendorf
tubes, mixed gently by swirling on ice, and centrifuged
at 15,0009g for 20 min at 4 C. The supernatant was
used to determine protein concentration by Bradford’s
method [18]. The protein in different cell lysates (40 lg)
was separated on SDS-polyacrylamide gel electrophoresis
(PAGE) and electrophoretically transferred on to PVDF
membrane. Membrane was blocked with 5 % Carnation
fat-free milk for 1 h at room temperature. Antibody
[anti-ERa or anti-PR in blocking solution (1:500)] was
added and incubated for 1 h, washed and incubated with
anti-mouse antibody-HRP (1:500) for ERa and PR pro-
teins, and anti-rabbit antibody-HRP (1:500) for GAPDH
protein for 1 h at room temperature. Immunoreactive
proteins were visualized using Luminata Forte Western
HRP substrate and as per the specifications provided by
the supplier in a Syngene Gel Documentation system
(MD, USA). Immunoreactive bands were quantified
using image analysis software (ImageJ).
Statistical analysis
The MTT assay and the images of semi-quantitative RT-
PCR gel data were analyzed by student t test and one-way
ANOVA followed by post hoc Tukey test. Values were
considered statistically significant if *P\ 0.05,
**P\ 0.005 compared to control and from E2-treated
samples if #P\ 0.005.
Table 1 Sequence of primers used for the amplification of different nuclear receptors, AP-1 factors, and b-actin
Gene Primer Sequence (50?30) Annealing temp (C) Product size (bp) Ref.
Nuclear receptors
ERa F: TACTGCATCAGATCCAAGGG
R: ATCAATGGTGCACTGGTTGG
61 650 [14]
ERb F: TGAAAAGGAAGGTTAGTGGGAACC
R: TGGTCAGGGACATCATCATGG
60 528 [14]
PR F: AGTCAGAGTTGTGAGAGCAC
R: AAAGAAGTTGCCTCTCGCCT
58 251 Present study
GR F: TGGTTTTGTCAAGCCCAGT
R: TTCCACCAATTCCCGTTGGT
62 290 Present study
AP-1 factors
c-Jun F: GCCTACAGATGAACTCTTTCTGGC
R: CCTGAAACATCGCACTATCCTTTG
64 525 [15]
Jun-B F: CCAGTCCTTCCACCTCGACGTTTACAAG
R: GACTAAGTGCGTGTTTCTTTTCCACAGTAC
58 257 [15]
Jun-D F: CGCAGCCTCA AACCCTGCCT TTCC
R: AAACAGGAATGTGGACTCGTAG
64 500 [15]
Fra-1 F: AGGAAGGAACTGACCGAC
R: GAAGGGGAGGAGACATTG
60 497 [15]
Fra-2 F: AGGAGGAGAGATGAGCAG
R: GGATAGGTGAAGACGAGG
60 518 [15]
c-Fos F: TCTTCCTTCGTCTTCACC
R: AATCAGAACACACTATTGCC
58 577 [15]
Fos-B F: TGTCCCAGGGAAATGTTTCAGGC
R: ACTGGTAGTTCCGCTGGTGGAAGG
56 451 Present study
b-actin F: TACCACTGGCATCGTGATGGACT
R: TCCTTCTGCATCCTGTCGGCAAT
62 516 [15]
Columns 3 and 4 show annealing temperatures and the size of the amplified products
F forward, R reverse
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Results
E2 or P4 induces proliferation, but Dex decreased
the viability of MCF-7 cells
In the Estradiol-17b-treated MCF-7 cells, there was a
marginal increase in the proliferation at 10 and 50 nM, but
showed more than 30 % increase at 100 nM E2. However,
the cell number decreases and plateaus off at higher con-
centrations of 0.5 and 1 lM of E2, respectively (Fig. 1a).
Figure 1b shows that P4 induces proliferation of MCF-7
cells with maximum of 36 % at 150 nM. However, at
higher concentrations of P4, the proliferation decreases and
plateaus off. When treated with Dex, cell proliferation was
decreased marginally in a dose-dependent manner, and
there was significant decrease (26 %) at 200 nM (Fig. 1c).
Cells treated with E2 in combination with Dex or P4 in
combination with Dex show decreased viability compared
to E2- (100 nM) or P4 (150 nM) alone-treated cells
(Fig. 1d). The results suggested that Dex appears to inhibit
E2- or P4-induced effects in MCF-7 cells.
ER antagonist (ICI 182,780) and PR antagonist
(RU486) decrease the viability of MCF-7 cells
To study the effect of nuclear receptor down-regulators
(NRRDs) ICI 182,780 and RU486 on the viability of MCF-
7 cells, the cells were treated with or without different
concentrations of ICI 182,780 (10–100 nM) or RU486
(10–1000 nM) for 48 h. Cell viability was measured by
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Fig. 1 Effect of different concentrations of (a) E2 (b) P4 (c) Dex
(d) E2 or P4 or E2 and Dex or P4 and Dex on the viability of MCF-7
cells. Cells were treated with or without different concentrations of
E2 (10–1000 nM) or P4 (10–1000 nM) or Dex (10–500 nM) and E2
(100 nM) or P4 (100 nM) or E2 (100 nM) and Dex (100 nM) and P4
(150 nM) and Dex (100 nM) in a 96-well plate for 48 h, and the cell
viability was measured by MTT assay. Results were expressed as %
viability of cells as compared to control (mean ± SD, n = 3). Values
are significantly different from control if *P\ 0.05, using student
t test. The results are shown as a representative of three independent
experiments
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MTT assay. Results show that the cell viability was
decreased in a dose-dependent manner, and a maximum of
20 and 25 % decrease was observed with ICI 182,780 at 10
and 25 nM, respectively. At higher concentrations, the cell
number plateaus off (Fig. 2a). Cell viability was not found
to be varied greatly when cells were treated with RU486,
but only 10 % decrease in the cell viability was observed
with lower concentrations (10 and 50 nM), while a maxi-
mum of 15 % decrease in cell viability was observed at
1 lM concentration of the inhibitor (Fig. 2b).
E2 induces ER, down-regulates PR and GR
MCF-7 cells were treated with E2 (100 nM) or Dex
(100 nM) or P4 (150 nM) or E2 (100 nM) in combination
with Dex (100 nM) or P4 (150 nM) in combination with
Dex (100 nM) for 48 h, and the expression of ERa, PR,
and GR mRNAs was analyzed. Results show that the
expression of ERa mRNA was significantly induced by all
steroid hormone treatments, and a maximum increase of
twofold was observed with E2 alone or Dex alone treat-
ment, while P4 alone shows 2.2-fold increase in the
expression. Whereas, the cells treated with Dex along with
E2 or P4 show significant decrease in the expression of
ERa mRNA compared to E2 and P4 alone treatments, and
ERb mRNA was found to be less expressed in all the
treatments (data not shown). Analysis of PR mRNA shows
that E2 and Dex alone or in combination decreased the
expression compared to control, while P4 alone shows
marginal decrease in PR expression. Whereas, analysis of
expression of GR mRNAs shows that the Dex or P4 alone
or in combination induced the expression by 2.5-, 2- and
2-fold, respectively, while E2 treatment shows significant
decrease in the expression by more than 80 % compared to
control. Cells treated with Dex in combination with E2
show significant decrease in the expression of GR mRNAs
compared to Dex alone-treated cells (Fig. 3a).
MCF-7 cells treated with steroid hormones in combi-
nation with ICI 182,780 or RU486 for 48 h show the
variable expression pattern of mRNAs of steroid receptors.
Cells treated with E2 and ICI decreased ERa expression by
58 % compared to control. However, Dex and RU486
show 1.4-fold increase in the ERa mRNA expression,
while cells treated with P4 and RU486 show no change in
the expression of ERa mRNA compared to control. The
cells treated with E2 and ICI or Dex and RU486 show 2.8-
and 2.5-fold increase in PR mRNA expression, respec-
tively, compared to control. But the cells treated with P4
and RU486 shows 62 and 58 % decrease in PR, respec-
tively, compared to cells treated with E2 and ICI or Dex
and RU486. Meanwhile, Dex and RU486, and P4 and
RU486 show 70 and 79 % decrease in GR mRNA
expression, respectively, compared to E2- and ICI-treated
cells. But there is less or no change in PR expression in the
cells treated with P4 and RU486 compared to control
(Fig. 3b).
E2 induces ERa protein, and Dex down-regulates
ERa and PR protein levels
MCF-7 cells treated with E2 alone show significant
increase in ERa protein level by more than 20 % compared
to control, and Dex found to reduce ERa protein by more
than 50 and 68 %, respectively, when treated alone and in
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Fig. 2 Effect of different concentrations of steroid antagonists
(a) ICI 182,780 and (b) RU486 on the viability of MCF-7 cells.
Cells were treated with or without different concentrations of ICI
182,780 (10–100 nM) and RU486 (10–1000 nM) in a 96-well plate
for 48 h, and the cell viability was measured by MTT assay. Results
were expressed as % viability of cells as compared to control
(mean ± SD, n = 3). Values are significantly different from control
if *P\ 0.05 and **P\ 0.005, using student t test. The results are
shown as a representative of three independent experiments
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Fig. 3 Effect of a Steroid hormones (E2 or Dex or P4) alone or in
combination and b Steroid hormone antagonists ICI 182,780 and
RU486 in combination with E2 or Dex or P4 on the expression of ER,
PR, and GR mRNAs in MCF-7 cells (c) Immunoblot analysis of
steroid hormones (E2 or Dex or P4) alone or in combination on the
expression of ER and PR proteins. Cells were treated with E2
(100 nM) or Dex (100 nM) or P4 (150 nM) or E2 (100 nM) and Dex
(100 nM) or P4 (150 nM) and Dex (100 nM) or E2 (100 nM) and ICI
(10 nM) or Dex (100 nM) and RU486 (10 nM) or P4 (150 nM) and
RU486 (10 nM) for 48 h, and expression of mRNAs of steroid
receptors was measured by semi-qRT-PCR technique. For
immunoblotting, the cells were treated with E2 (100 nM) or Dex
(100 nM) or P4 (150 nM) or E2 (100 nM) and Dex (100 nM) or P4
(150 nM) and Dex (100 nM) for 48 h. Cell lysates were prepared
using lysis buffer, and equal amount of protein (40 lg) containing cell
lysates were separated by SDS-PAGE, transferred to PVDF mem-
brane, and analyzed by immunoblotting using ERa, PR, and GAPDH
antibodies. The expressed protein level of GAPDH was used as a
control. Data presented as mean ± SD, n = 3. Differences in the
expression of mRNAs or protein levels are statistically significant: if
*P\ 0.05 compared with controls, #P\ 0.05 compared with E2-
induced values, and **P\ 0.005 compared with P4-induced values,
using one-way ANOVA followed by post hoc Tukey test. The bar
graph represents the densitometric analysis of mRNAs or protein
levels
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combination with E2 compared to E2 alone-treated cells.
Similarly, Dex found to reduce PR protein level by 25 and
27 %, respectively, when treated alone and in combination
with P4 compared to P4 alone-treated cells (Fig. 3c).
Dex down-regulates E2- or P4-induced AP-1
mRNAs
In order to study the combinatorial effect of steroid hor-
mones, MCF-7 cells were treated with or without steroid
hormones (E2 or Dex or P4 or E2 and Dex or P4 and Dex or
E2 and P4 or E2 and P4 and Dex) or steroid hormones in
combination with antagonists (E2 and ICI or Dex and
RU486 or P4 and RU486) for 48 h, and the differential
expression pattern of AP1 mRNAs were measured by semi-
q-RT-PCR, and relative mRNA levels were analyzed. The
results show that the cells treated with E2 significantly
induced the expression of c-Jun, Fra-1 by 1.8- and 1.7-fold,
respectively, compared to control. However, the cells
treated with P4 also show induced expression of c-Jun,
while Dex decreased the expression of c-Jun, Fra-1, and
Fra-2 when used in combination with E2 compared to E2
alone-treated cells (Fig. 4a). The results depicted in Fig. 4b
show that in the cells treated with both E2 and P4, there was
a significant increase in the expression of mRNAs of c-Jun
by 2.7-fold, c-Fos by 2.75-fold, Fra-1 and Fra-2 mRNAs by
1.5-fold compared to control. Cells treated with Dex along
with E2 and P4 reduced the expression of mRNAs of c-Jun
and Fra-2 by 61 and 20 %, respectively, compared to E2-
and P4-treated cells. Further, marginal reduction in the
c-Fos and Fra-1 mRNAs suggested that P4 appears to have
synergistic effect with E2, while Dex has antagonistic effect
of E2 in MCF-7 cells (Fig. 4b).
MCF-7 cells treated with E2 in combination with antag-
onist of E2 show that ICI significantly reduced the expression
of c-Jun, c-Fos, and Fra-1 mRNAs by 75, 49.5, and 67 %,
respectively, compared to control, and the cells treated with
P4 and RU486 show that the expression of c-Fos and Fra-1
mRNAs were decreased by 20 and 70 %, respectively.
Whereas, in the cells treated with Dex and RU486, Fra-1
mRNA levelwas significantly reduced, and therewas little or
no effect on the expression ofmRNAs of c-Jun and c-Fos, but
Fra-2 mRNA was significantly induced by 5.7-fold com-
pared to control. The results suggest that RU486 being an
antagonist blocking the action of Dex, and hence it induced
the expression of Fra-2 mRNA in MCF-7 cells (Fig. 4c).
Discussion
In mammals, the development and differentiation of
mammary gland are regulated by sex steroid hormones
(estrogen and progesterone) produced by the developing
ovary. The development of the gland also depends on
physical, molecular, and often reciprocal interactions of
stromal and epithelial compartments [19]. Steroid hor-
mones such as estrogen, progesterone including glucocor-
ticoids cross-talk to exhibit variable transcriptional
responses in mammary gland development. Over-expres-
sion of some of the early oncogenes such as AP-1 factors
probably results in the development of breast cancer.
Mechanism of cross-talk between the steroid hormones,
their receptors, and role of AP-1 proteins in the develop-
ment of cancer are yet to be understood. Hence, the present
study was undertaken to understand the role of ER and PR
including GR in the regulation of the expression of AP-1
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Fig. 4 Effect of a Steroid hormones (E2 or Dex or P4) or (b) steroid
hormones in combination (E2 and P4 or E2 and P4 and Dex), or
(c) steroid hormones in combination with their antagonists (E2 and
ICI or Dex and RU486 or P4 and RU486) on the expression of AP-1
factors in MCF-7 cells. Cells were treated with or without steroid
hormones (E2 or Dex or P4) or in combination (E2 and Dex or P4 and
Dex or E2 and P4 or E2, P4 and Dex), or with steroid hormone
antagonists (E2 and ICI or Dex and RU486 or P4 and RU486) for
48 h. Total RNA was isolated, and AP1 factors were analyzed on 1 %
agarose gel. Data presented as mean ± SD, n = 3. Values are
significantly different in figure (a) from the control if **P\ 0.05 and
**P\ 0.05 and from E2 alone if #P\ 0.005, in figure (b) *P\ 0.05
from E2 and P4 samples, and in figure (c) if *P\ 0.05 from control
and if **P\ 0.05 from steroid hormones and antagonists-treated
samples using one-way ANOVA followed by post hoc Tukey test.
The results are shown as representative of three independent
experiments
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factors. In most of the breast cancers, the cells are found to
be triple positive (ER, PR, and GR responsive), and at later
point of time lose the expression of receptors and become
much more aggressive tumors. MCF-7 cells used in our
study were found to be triple positive as ER, GR, and PR
mRNAs were expressed, and hence used to understand the
cross-talk between the steroid hormones and their recep-
tors. Both E2 and P4 at physiological concentration induce
proliferation. Our study also shows that both E2 and P4
induce the expression of ERa at mRNA and protein levels,
and proliferation is through the steroid receptor ERa. P4
potentially induces ERa at mRNA level, but the effect was
less seen at protein level. However, the expression of ERb
mRNA was negligible (data not shown) confirming our
earlier studies [14]. Studies carried out in different labo-
ratories suggested that ERa-positive cells induced by E2
release paracrine growth factors such as EGF which
mediates ERa-mediated mammary gland epithelial cell
proliferation. We also found that with increase in the dose
of E2 in the treatment of MCF-7 cells, the proliferation was
increased [20].
MCF-7 cells express all the three NRs (ERa, PR, and
GR); as the NRs and their hormones are closely related,
there is every possibility of extensive interplay and
downstream signaling. It is a well-known fact that the
combinatorial expression of all the NRs is important in
determining the prognosis and avenues for the treatment
[21, 22]. However, fewer studies have been carried out on
the expression of all the steroid hormone receptors by
examining the action of one hormone at a time, and mostly
a reductionist approach was used [23]. Studies using GR
with PR [24, 25] or ERa with RAR [26, 27] show both
competitive and co-operative interactions. Hence, in our
studies, the expression of all the three NRs (ERa, PR, and
GR) was examined for the action of E2 or Dex or P4 alone
or in combination of E2 with Dex or P4 with Dex. Our
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studies show that all the steroid hormones (E2 or P4 or
Dex) induced the expression of ERa; however, combina-
tion of E2 or P4 with Dex reduced ERa expression, sug-
gesting that the proliferation or anti-proliferative effect
may be through ERa. P4 also stimulates the proliferation,
and probably the action is through ERa as earlier studies
have shown that the steroid action is through ERa in MCF-
7 cells [28].
Dex reduces the cell proliferation and shows opposing
effect of E2 in MCF-7 cells. Buxant et al. [29] showed that
concentration of Dex as low as 10-7 M reduced the pro-
liferation of MCF-7 cells by more than 30 % [29]. Several
studies also demonstrated the antagonistic effect of estro-
gen by glucocorticoids in ER/GR-positive breast and
uterine carcinoma cells. Using multiple estrogen-respon-
sive transcriptional assay system, steroid receptor co-acti-
vators (SRC 2, SRC 3) with MED 14 (mediator
component); it was found that GR recruits five-time ER
transcriptional responses under multiple hormone stimuli
using GFP-ERa, HeLa–PRL cells [23]. Dex counteracts the
stimulatory effect of E2 on MCF-7 cells and inhibits cell
proliferation, and the down-regulation of ER by GCs is by
attenuation and not by negative response. The inhibitory
action of Dex on the estradiol-induced cell proliferation
was confirmed by thymidine incorporation into DNA in
MCF-7 cells [30].
When both E2 and Dex hormones were added simulta-
neously, estradiol-stimulated transcription of genes was
found to be blocked by glucocorticoid hormone. Studies
show that Dex occupies several ER-binding regions (EBR),
and little or less sites are available for E2 binding to its
receptor ERa [8]. Further, with increasing the duration of
exposure time of Dex to MCF-7 cells, the GR predomi-
nantly localized in the nucleus binding to ERa. Probably,
this may be the reason for the receptor ERa to become
available more for Dex and less for E2 or P4, so that E2- or
P4-mediated transcriptional processes found to be down-
regulated. The mechanism of E2 regulation by GR and vice
versa is yet to be completely understood. Krishnan et al.
[31] demonstrated that E2 treatment causes substantial
suppression of GR mRNA and protein levels [31]. In our
study also E2 down-regulated the expression of GR, as the
cells were exposed longer to E2. Our studies on the
expression pattern of ER, PR, and GR mRNAs in MCF-7
cells with different steroid hormone treatments and in
combination show that E2, P4, and Dex alone induce ERa
mRNA, while Dex down-regulated E2- or P4-induced ERa
at both mRNA and protein levels. Thus, Dex attenuates E2
responses, but the mechanism by which GC inhibits the E2
activity is not completely understood. However, earlier
study showed that Dex induced and activated the estrogen
sulfotransferase enzyme activity that sulfonate E2, and
sulfonated E2 cannot bind and activate ER- and E2-
mediated genes. In the presence of E2, Dex recruits GR
binds to ERa binding region and destabilizes ERa tran-
scriptional complex [32]. Thus, Dex inhibits E2-dependent
proliferation and down-regulates the ERa-regulated target
genes. Earlier studies also show that Dex has stimulatory
effect in solid tumors including MCF-7 cells. In general,
GCs use two mechanisms to do so: an anti-apoptotic, pro-
survival action combined with a pro-proliferative action
[33] which supports our studies, where Dex induces ERa
mRNA expression that is involved in proliferation. In our
studies, RU486 exerts both anti-progestin and anti-gluco-
corticoid activity by reducing the expression of both GR
and PR mRNAs. Although RU486 is an anti-progestin, the
inhibitor was found to be more effective towards the
expression of GR mRNA compared to PR mRNA when
used along with Dex. Further, we demonstrated that RU486
treatment along with Dex or P4 increased ERa mRNA
suggesting that the suppression of GR mRNA has a posi-
tive effect on the expression. This further confirms the
interplay of GR and ER.
In our study, all the steroid hormone treatments reduced
the expression of PR mRNA as well as PR protein which
suggested that E2 or Dex may compete for PR-binding
regions like in the case of ER binding with more affinity,
and hence PR sites are less available for progesterone
binding, resulting in reducing the expression of PR and that
needs further investigation. However, P4 reduced the
expression of PR mRNA, and less effect was observed at
PR protein level. This is probably due to P4 binding to ERa
or GR dimerization of PR that may have resulted because
of the constant exposure. Earlier studies show that the
expression of PR is independent of E2 expression in T-47D
breast cancer cells. Estrogen-pre-treated breast cancer cells
show tenfold induction in PR levels than those with
estrogen-nontreated cells. It is difficult to study the intrinsic
biological role of PR in breast cancers precisely because of
its inter-dependent relationship on ERa and concordance
between the levels of ER and PR in breast cancers [34–36].
PR action is dependent on the hormonal context with
concurrent estrogen treatment producing a unique tran-
scriptomic response to progesterone. The master regulator
of progesterone response in breast cancer appears to be
estrogen dependent which regulates PR abundance, thereby
permitting PR–DNA binding, which suggests that the
action of estrogen and progesterone is inextricably linked.
ER and PR have the longest co-existence in relation to
other receptors such that ERa-mediated up-regulation of
PR abundance permits activity in response to progesterone,
and PR in turn regulates a subset of ERa actions
[28, 37, 38].
Our study also show that the MCF-7 cells treated with
E2 increased the expression of mRNAs of c-Jun, c-Fos,
and Fra-1, confirming our previous observation [14], while
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P4 appears to have induced effect on the expression of
c-Jun and Fra-1 mRNAs. This confirms that P4 has E2-like
effects. However, cells treated with E2 and Dex show
significant decrease in c-Jun and c-Fos expression, sug-
gesting that the Dex inhibits E2-induced expression
specifically and may play a major role in proliferation. E2
together with P4 induces the expression of c-Jun/c-Fos and
Fra-2, suggesting the synergistic action of ER and PR,
further confirming that P4 acts like E2 [39, 40]. However,
Dex inhibited the expression of c-Jun, c-Fos, and Fra-2
induced by E2 and P4, and suggested the antagonistic
effect of Dex. Use of ICI proves the role of E2 in the
expression of c-Jun, c-Fos, and Fra-1 mRNAs. Dex and
RU486 induced Fra-2 by more than fivefold, and this may
be probably due to blocking of Dex action through GR or
PR that needs to be investigated. Previous studies show that
the ratio of Jun:Fos (c-Jun:c-Fos or Jun-D:c-Fos or Jun-
D:Fra-1) in a given cell changes the steroid response to
Dex at AP-1 site and proliferin complex (GRE/AP-1)
response element. The result of our study suggested that
ER, PR, and GR play a major role in the proliferation of
cells through c-Jun, c-Fos, and fra-1 AP-1 factors.
In conclusion, our study suggested that breast cancer
cells express ER, PR, and GR, and there exist extensive
cross-talk between them through steroid hormones. Thus,
glucocorticoids and related compounds can be used as anti-
estrogenic and anti-progesterone agents in the multi-hor-
mone therapy and in the treatment of breast cancer.
Acknowledgments The authors wish to express their gratitude to the
Department of Science and Technology-Promotion of University
Research and Scientific Excellence (DST-PURSE) [SR/59/Z-23/
2010/38(c)] and University Grant Commission Centre with Potential
for Excellence in Particular Area (UGC-CPEPA) [8-2/2008(NS/PE)],
New Delhi for providing financial support. The authors also wish to
express their gratitude to the Department of Microbiology and
Biotechnology, Bangalore University, Bengaluru for providing the
DST-FIST, UGC-SAP, and department facility.
References
1. Brisken C, O’Malley B (2010) Hormone action in the mammary
gland. Cold Spring Harb Perspect Biol 2:a003178. doi:10.1101/
cshperspect.a003178
2. Humphreys RC, Lydon J, O’Malley BW, Rosen JM (1997)
Mammary gland development is mediated by both stromal and
epithelial progesterone receptors. Mol Endocrinol 11:801–811.
doi:10.1210/mend.11.6.9891
3. Contro` V, Basile JR, Proia P (2015) Sex steroid hormone
receptors, their ligands, and nuclear and non-nuclear pathways.
AIMS Mol Sci 2:294–310. doi:10.3934/molsci.2015.3.294
4. Simoncini T, Genazzani AR (2003) Non-genomic actions of sex
steroid hormones. Eur J Endocrinol 148:281–292
5. Clarke CL, Sutherland RL (1990) Progestin regulation of cellular
proliferation. Endocr Rev 11:266–301. doi:10.1210/edrv-11-2-
266
6. Vesely PW, Staber PB, Hoefler G, Kenner L (2009) Translational
regulation mechanisms of AP-1 proteins. Mutat Res 682:7–12.
doi:10.1016/j.mrrev.2009.01.001
7. Bjornstrom L, Sjoberg M (2005) Mechanisms of estrogen
receptor signaling: convergence of genomic and nongenomic
actions on target genes. Mol Endocrinol 19:833–842. doi:10.
1210/me.2004-0486
8. Karmakar S, Jin Y, Nagaich AK (2013) Interaction of gluco-
corticoid receptor (GR) with estrogen receptor (ER) alpha and
activator protein 1 (AP1) in dexamethasone-mediated interfer-
ence of ERalpha activity. J Biol Chem 288:24020–24034. doi:10.
1074/jbc.M113.473819
9. Uht RM, Anderson CM, Webb P, Kushner PJ (1997) Transcrip-
tional activities of estrogen and glucocorticoid receptors are
functionally integrated at the AP-1 response element.
Endocrinology 138:2900–2908. doi:10.1210/endo.138.7.5244
10. Leo JC, Guo C, Woon CT, Aw SE, Lin VC (2004) Glucocorticoid
and mineralocorticoid cross-talk with progesterone receptor to
induce focal adhesion and growth inhibition in breast cancer
cells. Endocrinology 145:1314–1321. doi:10.1210/en.2003-0732
11. Wakeling AE, Bowler J (1987) Steroidal pure antioestrogens.
J Endocrinol 112:R7–R10
12. Osborne CK, Wakeling A, Nicholson RI (2004) Fulvestrant: an
oestrogen receptor antagonist with a novel mechanism of action.
Br J Cancer 90(Suppl 1):S2–S6. doi:10.1038/sj.bjc.6601629
13. Sharma SC, Purohit P, Rao AJ (1993) Role of oestradiol-17b in
the regulation of synthesis and secretion of human chorionic
gonadotrophin by first trimester human placenta. J Mol Endo-
crinol 11:91–101
14. Babu RL, Naveen Kumar M, Patil RH, Devaraju KS, Ramesh
GT, Sharma SC (2013) Effect of estrogen and tamoxifen on the
expression pattern of AP-1 factors in MCF-7 cells: role of c-Jun,
c-Fos, and Fra-1 in cell cycle regulation. Mol Cell Biochem
380:143–151. doi:10.1007/s11010-013-1667-x
15. Patil RH, Babu RL, Naveen Kumar M, Kiran Kumar KM, Hegde
SM, Ramesh GT, Chidananda Sharma S (2015) Apigenin inhibits
PMA-induced expression of pro-inflammatory cytokines and AP-
1 factors in A549 cells. Mol Cell Biochem 403:95–106. doi:10.
1007/s11010-015-2340-3
16. Periyakaruppan A, Kumar F, Sarkar S, Sharma CS, Ramesh GT
(2007) Uranium induces oxidative stress in lung epithelial cells.
Arch Toxicol 81:389–395. doi:10.1007/s00204-006-0167-0
17. Sharma SC, Clemens JW, Pisarska MD, Richards JS (1999)
Expression and function of estrogen receptor subtypes in granu-
losa cells: regulation by estradiol and forskolin. Endocrinology
140:4320–4334. doi:10.1210/endo.140.9.6965
18. Bradford MM (1976) A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing the
principle of protein-dye binding. Anal Biochem 72:248–254
19. Cunha GR, Hom YK (1996) Role of mesenchymal-epithelial
interactions in mammary gland development. J Mammary Gland
Biol Neoplasia 1:21–35
20. Tan H, Zhong Y, Pan Z (2009) Autocrine regulation of cell
proliferation by estrogen receptor-alpha in estrogen receptor-al-
pha-positive breast cancer cell lines. BMC Cancer 9:31. doi:10.
1186/1471-2407-9-31
21. Buxant F, Engohan-Aloghe C, Noel JC (2010) Estrogen receptor,
progesterone receptor, and glucocorticoid receptor expression in
normal breast tissue, breast in situ carcinoma, and invasive breast
cancer. Appl Immunohistochem Mol Morphol 18:254–257.
doi:10.1097/PAI.0b013e3181c10180
22. Pan D, Kocherginsky M, Conzen SD (2011) Activation of the
glucocorticoid receptor is associated with poor prognosis in
estrogen receptor-negative breast cancer. Cancer Res
71:6360–6370. doi:10.1158/0008-5472.can-11-0362
Mol Cell Biochem
123
23. Bolt MJ, Stossi F, Newberg JY, Orjalo A, Johansson HE, Mancini
MA (2013) Coactivators enable glucocorticoid receptor recruit-
ment to fine-tune estrogen receptor transcriptional responses.
Nucleic Acids Res 41:4036–4048. doi:10.1093/nar/gkt100
24. Guo CM, Zhu XO, Ni XT, Yang Z, Myatt L, Sun K (2009)
Expression of progesterone receptor A form and its role in the
interaction of progesterone with cortisol on cyclooxygenase-2
expression in amnionic fibroblasts. J Clin Endocrinol Metab
94:5085–5092. doi:10.1210/jc.2009-0832
25. Ponta H, Cato AC, Herrlich P (1992) Interference of pathway
specific transcription factors. Biochim Biophys Acta
1129:255–261
26. Ross-Innes CS, Stark R, Holmes KA, Schmidt D, Spyrou C,
Russell R, Massie CE, Vowler SL, Eldridge M, Carroll JS (2010)
Cooperative interaction between retinoic acid receptor-alpha and
estrogen receptor in breast cancer. Genes Dev 24:171–182.
doi:10.1101/gad.552910
27. Hua S, Kittler R, White KP (2009) Genomic antagonism between
retinoic acid and estrogen signaling in breast cancer. Cell
137:1259–1271. doi:10.1016/j.cell.2009.04.043
28. Need EF, Selth LA, Trotta AP, Leach DA, Giorgio L, O’Loughlin
MA, Smith E, Gill PG, Ingman WV, Graham JD, Buchanan G
(2015) The unique transcriptional response produced by concur-
rent estrogen and progesterone treatment in breast cancer cells
results in upregulation of growth factor pathways and switching
from a Luminal A to a Basal-like subtype. BMC Cancer 15:791.
doi:10.1186/s12885-015-1819-3
29. Buxant F, Kindt N, Laurent G, Noel JC, Saussez S (2015)
Antiproliferative effect of dexamethasone in the MCF-7 breast
cancer cell line. Mol Med Rep 12:4051–4054. doi:10.3892/mmr.
2015.3920
30. Zhou F, Bouillard B, Pharaboz-Joly MO, Andre J (1989) Non-
classical antiestrogenic actions of dexamethasone in variant
MCF-7 human breast cancer cells in culture. Mol Cell Endocrinol
66:189–197
31. Krishnan AV, Swami S, Feldman D (2001) Estradiol inhibits
glucocorticoid receptor expression and induces glucocorticoid
resistance in MCF-7 human breast cancer cells. J Steroid Bio-
chem Mol Biol 77:29–37
32. Gong H, Jarzynka MJ, Cole TJ, Lee JH, Wada T, Zhang B, Gao J,
Song WC, DeFranco DB, Cheng SY, Xie W (2008) Glucocorti-
coids antagonize estrogens by glucocorticoid receptor-mediated
activation of estrogen sulfotransferase. Cancer Res
68:7386–7393. doi:10.1158/0008-5472.can-08-1545
33. Gundisch S, Boeckeler E, Behrends U, Amtmann E, Ehrhardt H,
Jeremias I (2012) Glucocorticoids augment survival and prolif-
eration of tumor cells. Anticancer Res 32:4251–4261
34. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV (2005) Biology
of progesterone receptor loss in breast cancer and its implications
for endocrine therapy. J Clin Oncol 23:7721–7735. doi:10.1200/
jco.2005.09.004
35. Fisher B, Wickerham DL, Brown A, Redmond CK (1983) Breast
cancer estrogen and progesterone receptor values: their distribu-
tion, degree of concordance, and relation to number of positive
axillary nodes. J Clin Oncol 1:349–358
36. Horwitz KB, Mockus MB, Lessey BA (1982) Variant T47D
human breast cancer cells with high progesterone-receptor levels
despite estrogen and antiestrogen resistance. Cell 28:633–642
37. Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, D’Assoro
AB, Ravindranathan P, Peng Y, Raj GV, Yee D, Lange CA
(2015) Progesterone receptor-B enhances estrogen responsive-
ness of breast cancer cells via scaffolding PELP1- and estrogen
receptor-containing transcription complexes. Oncogene
34:506–515. doi:10.1038/onc.2013.579
38. Daniel AR, Gaviglio AL, Knutson TP, Ostrander JH, Yee D,
Lange CA (2013) Unliganded progesterone receptors augment
estrogen-induced growth of breast cancer cells via co-regulation
of estrogen receptor target genes. Cancer Res 73:3572–3578
39. Amsterdam A, Tajima K, Sasson R (2002) Cell-specific regula-
tion of apoptosis by glucocorticoids: implication to their anti-
inflammatory action. Biochem Pharmacol 64:843–850
40. Lippman M, Bolan G, Huff K (1976) The effects of glucocorti-
coids and progesterone on hormone-responsive human breast
cancer in long-term tissue culture. Cancer Res 36:4602–4609
Mol Cell Biochem
123
